Navigation Links
SXC Health Solutions to present at the 2008 Thomas Weisel Partners Healthcare Conference
Date:8/21/2008

LISLE, IL, Aug. 21 /PRNewswire-FirstCall/ - SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC), a leading provider of pharmacy benefits management services, announces that Mark Thierer, President and CEO, and Jeff Park, CFO, will present at the 2008 Thomas Weisel Partners Healthcare Conference at the Four Seasons Hotel in Boston, Massachusetts. SXC's presentation will take place on Wednesday, September 3, 2008 at 2:40 pm ET.

SXC's presentation will be webcast live. To access the webcast go to: http://www.veracast.com/webcasts/twp/healthcare08/79112295.cfm

About SXC Health Solutions Corp.

SXC Health Solutions Corp. is a leading provider of pharmacy benefits management (PBM) services and Health Care Information Technology (HCIT) solutions to the healthcare benefits management industry. The Company's product offerings and solutions combine a wide range of software applications, application service provider (ASP) processing services and professional services, designed for many of the largest organizations in the pharmaceutical supply chain, such as Federal, provincial, and, state and local governments, pharmacy benefit managers, managed care organizations, retail pharmacy chains and other healthcare intermediaries. SXC is headquartered in Lisle, Illinois with 13 locations in the US and Canada. For more information please visit http://www.sxc.com.


'/>"/>
SOURCE SXC Health Solutions Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... -- ViroPharma Incorporated,(Nasdaq: VPHM ) tod...ntal,Biologics License Application (sBLA) to the ...ze(TM) C1 Inhibitor (human) as a treatment for acu... The sBLA is based on a re-analysis and resubmis...nt study of Cinryze and interim data from an ongoi...
(Date:12/1/2008)... ETHICON, Inc., a Johnson & Johnson company, a...re of its Professional Wound Care business to One ...on are not being disclosed. , , Under the t...cquired the Professional Wound Care product portfo...s as PROMOGRAN Matrix Wound Dressing, TIELLE Hydro...
(Date:12/1/2008)...als, commitment and resources , , MOND...cism that it has done a poor job safeguarding the ...istration released a report Monday detailing its e...mportant changes in 2008 was the agency,s initiati...cal health departments to protect the food supply,...
(Date:12/1/2008)...ndation announces the 2008 winners of the Lee C. H...ipients, Dr. Gerard Karsenty of the Columbia Unive...weig of Rockefeller University received the award ...ure and control of rheumatic diseases. , Dr. Ka...opment and function of the skeletal system. A grad...
Breaking Medicine News(10 mins):Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4
...g to a Danish study conducted by Dr. Morten Anders...d colleagues it was found that doctors //who took ...end to prescribe the sponsor’s drugs. The study re...al Association. The research team said that this i...
...g to a study conducted by Yale university research...ter part of one's life resulted in an increased ra...people between the age group of 51 to 61 years. Th...pational and Environmental Medicine journal. Out o...
...n Cancer Support of UK has taken a strong campaign... conducted that said that in Scotland people spent...ital during treatment which is ?318 in Wales. The...parking costs be made free or subsidized. "These ...
...Stone, the killer of Lin and Megan Russell has pet...ake his mental health report// public since it wou... is is serving life for the two murders committed ...Clayton QC said that the parts of the mental healt...
Other Medicine News:
(Date:11/26/2008).... 26 Children whose eye...antly increased risk of developing mental illness ...yo Clinic study published this month in Pediatrics... Pediatrics. , , The retrospective study ex...rabismus (misaligned eyes) and compared them with ...
(Date:11/25/2008)...espondents against expanding statin use broadly in...LS, N.J., Nov. 25 JUPITER, a clini...rdiovascular risk of healthy patients with elevate...lder adults, according to a national poll directed...took part in the online poll conducted by medical ...
(Date:11/25/2008)...RNewswire-FirstCall/ -- CardioVascular,BioTherape...today that it has,dosed the first patient in Nort...ical trial to treat patients with severe coronary ...eatment of CORonary heart Disease) trial will incl...lled doses in approximately 120,patients with sev...
(Date:11/24/2008)... innovation leadership and long-term commitment to...ov. 24 Schering-Plough C...l update on boceprevir, its lead investigational o...ase III development. The company believes bocepre...est-in-class protease inhibitor for treating chron...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9UNC scientists turn human skin cells into insulin producing cells 4935 1UNC scientists turn human skin cells into insulin producing cells 4935 2Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 1Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 2Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 3Final Patient Enrolled In Large Data Registry of Incisionless Gastric Pouch and Stoma Reduction Procedure 26533 4The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 1The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 2The Childrens Hospital of Philadelphia Erects the Final Beam of its Newest Research Building 26529 3Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 1Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 2Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 3Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 4Multi Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients 3080 5
...--Apr 26, 2007 - Northfield,Laboratories Inc. (Nas...rch organization has informed the Company that the... III trauma trial with,PolyHeme(R), the Company,s ...bstitute, will not be complete until May., About N...nc. is a leader in developing an,oxygen-carrying r...
...emonstrates dramatic,benefits of adding Diovan to ...to superior outcomes for,Diovan patients , , , ... from the independent,Jikei Heart Study, published...d pressure lowering medication Diovan® to,conv... in,cardiovascular events and a 40% reduction in s...
Other Medicine Technology:Northfield Laboratories Investor Update 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7
... technology, the wire crosses the lesion first, in... other actions, including filter placement and ret...hen occur over the wire., ,Emboshield is desig...carotid stenting procedure, and it is the only fil...
...ip product, the Super Premium ALPHA 10 System offe...atility in an intuitive and ergonomically designed...or Perinatology/Maternal & Fetal Medicine Speciali...Breast Imaging, and General Imaging departments in...
...tra Laboratory has been uniquely designed to fit t...ks spanning multi-facilities. From test initiation...ts receivable, Centricity Ultra facilitates quick,...system modules are fully integrated and reside und...
CELL-DYN Sapphire, our flagship solution for high-volume laboratories, utilizes patented MAPSS plus 3-color fluorescent technology for improved lab efficiency.
Medicine Products: